- Home
- DYOR vs EMBC Comparison
DYOR vs EMBC Comparison
Compare DYOR & EMBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DYOR | EMBC |
|---|---|---|
| Founded | 2025 | 1924 |
| Country | United States | United States |
| Employees | N/A | 1850 |
| Industry | Blank Checks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 230.9M | 200.5M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | DYOR | EMBC |
|---|---|---|
| Price | $10.04 | $3.35 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $18.50 |
| AVG Volume (30 Days) | 11.3K | ★ 3.6M |
| Earning Date | 01-01-0001 | 05-05-2026 |
| Dividend Yield | N/A | ★ 6.88% |
| EPS Growth | N/A | ★ 20.90 |
| EPS | N/A | ★ 0.67 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $1.17 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $4.96 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.87 | $2.77 |
| 52 Week High | $10.47 | $15.55 |
Technical Indicators
Market Signals| Indicator | DYOR | EMBC |
|---|---|---|
| Relative Strength Index (RSI) | 58.26 | 24.66 |
| Support Level | $9.93 | $2.77 |
| Resistance Level | $10.47 | $9.38 |
| Average True Range (ATR) | 0.02 | 0.23 |
| MACD | 0.00 | 0.17 |
| Stochastic Oscillator | 50.00 | 62.50 |
Price Performance
Historical ComparisonAbout DYOR Insight Digital Partners II Class A Ordinary Shares
Insight Digital Partners II is a blank check company.
About EMBC Embecta Corp.
Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.